

The Problem Space

Aphasia, a speech impairment disorder caused by brain damage often from strokes, affects language skills but not intelligence. Current assistive devices focus mostly on severe cases, leaving mild to moderate aphasia less supported. This, along with a lack of specialized therapists, highlights the global need for more accessible aphasia solutions.

The Solution

The first Context-Aware AI Communication Assistance for Aphasia. Revolutionary Features: Real-time, context-aware speech analysis, struggle detection, precise word retrieval using machine-learning, personalized progress tracking data.



find words easier during conversations



feel less isolated and more motivated to practice



engage in more social conversation

Tale helps our user



effectively track the word gains and inform the healthcare professionals

1 in 4 people

over age 25 will have a stroke in their lifetime

Up to \$7,392



additional cost per patient for Aphasia Care

1 in 3 Strokes

result in aphasia

2,000,000

People with Aphasia in US



Tale facilitates learning by providing users with prompted words and sentences in conversation contexts, allowing for repetition and reinforcement of language skills.

Proof of Concept Timeline

Validation from Neurologist from Swedish Hospital, Seattle

02/09/2024

02/05/2024

Early - stage establishment with UW Speech Clinic

Validation from Professor Emerita, specialized in Communication, Sciences and Disorder (CSD)

02/16/2024

First MVP User Test

02/13/2024

Early-stage establishment with University of Buffalo Professor on Parallel Distributed Network Database

Q1 2024

Competitive Landscape

Tale serves the mild to moderate speech impairment market with real-time assistance and competitive pricing. It offers personalized support and could reduce software prices by 20% without extra hardware costs, making it more accessible. The global speech impairment market is projected to reach USD 14.57 billion by 2030, and TALE targets segments like speech generating devices and speech therapy, estimated at USD 7.2 billion. With the potential to expand beyond aphasia patients to other speech impairments, TALE can capture a significant portion of these markets.

2030		
USD 553 Million	<small>First Priority</small>	Speech Generating Device
USD 6.67 Billion	<small>Second Priority</small>	Speech Pathology (Therapy) Services
USD 916 Million	<small>Third Priority</small>	Speech to Speech Translator
USD 14.57 Billion		Global Speech Impairment

Team

Aayush Kumar
Abhishek Singh
Ashwin Nishad
Ghea Suyono

Advisors

Prof. John Raiti, Ph.D, UW, Dept. of Electrical and Comp. Engineering
Ying Hao Chen, UW, Instructor for MS in Tech Innovation
Alejandro Estrada, Founder, Catorce Ventures
Consulted with
Dr. William Lou, Neurologist, Swedish Hospital, Seattle
Diane L. Kendall, MPH, Ph.D, Dept. of Speech and Hearing Sciences, UW
Avijit Tripathy, PM, Unlearn.Ai